IMNM
Immunome Inc.
$23.71
+$0.22(+0.94%)
50
Overall
50
Value
60
Tech
42
Quality
Market Cap
$1.41B
Volume
691.65K
52W Range
$7.15 - $27.65
Target Price
$35.54
Company Overview
| Mkt Cap | $1.41B | Price | $23.71 |
| Volume | 691.65K | Change | +0.94% |
| P/E Ratio | -4.8 | Open | $23.45 |
| Revenue | $9.0M | Prev Close | $23.49 |
| Net Income | $-293.0M | 52W Range | $7.15 - $27.65 |
| Div Yield | N/A | Target | $35.54 |
| Overall | 50 | Value | 50 |
| Quality | 42 | Technical | 60 |
No chart data available
About Immunome Inc.
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Immunome (IMNM) Receives a Buy from LifeSci Capital
TipRanks Auto-Generated Intelligence Newsdesk•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMNM | $23.71 | +0.9% | 691.65K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |